# A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

> clinical trial · VERIFIED · 2026-08-10

Status: RECRUITING · Sponsor: Genentech, Inc. · Condition: Breast Cancer

- Company: Genentech, Inc.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07100106

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.